Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Lipid-regulating drugs

PCSK9 inhibitors help patients reach cholesterol targets, review finds

Systematic review of data from more than 10,000 patients shows how anti-PCSK9 monoclonal antibodies can help patients achieve LDL-C targets as monotherapy or with statins.

Computer illustration of low-density lipoproteins (LDL) and PCSK9 bound to receptors

Source: Maurizio de Angelis / Science Photo Library

Computer illustration of low-density lipoprotein (LDL) molecules (round) and molecules of the enzyme proprotein convertase subtilisin/kexin type 9 (PCSK9, blue) bound to LDL receptor proteins (Y-shaped)

Many patients with hypercholesterolaemia do not achieve their recommended low-density lipoprotein cholesterol (LDL-C) target level despite treatment with statins.

In a systematic review, researchers looked at data from 21 phase III trials of the anti-PCSK9 monoclonal antibodies alirocumab and evolocumab for the treatment of hypercholesterolaemia. The data was from over 10,000 patients, most of whom received a PCSK9 inhibitor in addition to statins.

The team found that up to 87% of patients who received alirocumab and up to 98% who received evolocumab reached their LDL-C target when the antibodies were taken with statins, while 42–84% of patients who received antibodies as monotherapy achieved their LDL-C target.

Reporting in the British Journal of Clinical Pharmacology[1] (online, 4 October 2016), the researchers say the findings show that anti-PCSK9 antibodies can help patients with high cardiovascular risk achieve their LDL-C targets both as add-on therapy or as monotherapy for patients unable to tolerate statins.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20201897

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Computer illustration of low-density lipoproteins (LDL) and PCSK9 bound to receptors

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.